Comparative efficacy and safety profile of 4 vs 8 mg of silodosin once daily usage in patients with benign prostatic hyperplasia–related lower urinary tract symptoms divided into subgroups according to International Prostate Symptom Score severity

BACKGROUND: The purpose of this study was to compare once daily (QD) usage of 4 and 8 mg of silodosin in patients divided as those with moderate and with severe lower urinary tract symptoms (LUTSs) according to International Prostate Symptom Score (IPSS) categories in terms of effectiveness and adve...

Descripción completa

Detalles Bibliográficos
Autores principales: Gul, Abdullah, Coban, Soner, Turkoglu, Ali Riza, Guzelsoy, Muhammet, Ozturk, Murat, Kankilic, Nazim Abdulkadir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767940/
https://www.ncbi.nlm.nih.gov/pubmed/33425792
http://dx.doi.org/10.1016/j.prnil.2020.04.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767940/
https://www.ncbi.nlm.nih.gov/pubmed/33425792
http://dx.doi.org/10.1016/j.prnil.2020.04.002

Ejemplares similares